AKBA
Akebia Therapeutics, Inc. NASDAQ Listed Mar 20, 2014$1.18
Mkt Cap $316.5M
52w Low $1.13
1.7% of range
52w High $4.08
50d MA $1.39
200d MA $2.06
P/E (TTM)
-67.3x
EV/EBITDA
20.5x
P/B
11.0x
Debt/Equity
6.6x
ROE
-16.4%
P/FCF
6.1x
RSI (14)
—
ATR (14)
—
Beta
0.37
50d MA
$1.39
200d MA
$2.06
Avg Volume
3.0M
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
245 First Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 1.48 | -23.0% | -20.3% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.03 | -0.05 | -66.7% | 1.32 | -1.5% | -0.8% | -3.8% | -3.2% | +2.5% | -4.8% | — |
| Nov 10, 2025 | AMC | -0.06 | 0.00 | +103.3% | 1.67 | +0.6% | +8.4% | +2.2% | -4.9% | -5.1% | +5.4% | — |
| Aug 7, 2025 | AMC | -0.02 | 0.00 | +104.5% | 3.01 | +1.7% | +13.6% | -2.0% | -0.9% | -0.6% | -0.3% | — |
| May 8, 2025 | AMC | -0.03 | 0.03 | +200.0% | 2.62 | +0.0% | -2.7% | -4.7% | +2.1% | -1.2% | +3.7% | — |
| Mar 13, 2025 | AMC | -0.05 | -0.10 | -100.0% | 1.69 | +4.7% | +33.7% | +6.2% | +6.2% | +11.4% | -28.2% | — |
| Nov 7, 2024 | AMC | -0.05 | -0.10 | -100.0% | 1.87 | -1.6% | +3.7% | +2.6% | -2.0% | -1.5% | -3.1% | — |
| Aug 8, 2024 | AMC | -0.06 | -0.04 | +33.3% | 1.19 | +0.0% | -6.7% | +10.8% | +8.9% | +0.7% | +6.7% | — |
| May 9, 2024 | AMC | -0.09 | -0.09 | +0.0% | 1.33 | -6.0% | -9.0% | +6.6% | -4.7% | -4.1% | -3.4% | — |
| Mar 14, 2024 | AMC | 0.00 | 0.00 | +99.4% | 1.37 | +16.8% | +24.1% | +11.2% | -3.2% | +6.0% | +5.2% | — |
| Nov 8, 2023 | AMC | -0.09 | -0.08 | +11.1% | 0.96 | +1.0% | -5.2% | -1.9% | +3.4% | +11.6% | -2.9% | — |
| Aug 25, 2023 | AMC | -0.03 | -0.06 | -140.0% | 1.15 | +7.0% | +20.0% | +11.6% | -9.1% | -0.7% | -4.3% | — |
| May 8, 2023 | AMC | -0.15 | -0.14 | +6.7% | 1.06 | -3.8% | -0.9% | -1.9% | +2.9% | +6.6% | -3.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | BTIG | Maintains | Buy → Buy | — | $1.32 | $1.32 | +0.0% | +4.5% | +3.6% | -1.4% | -0.7% | +5.0% |
| Feb 25 | BTIG | Maintains | Buy → Buy | — | $1.24 | $1.25 | +0.8% | -2.4% | +9.1% | -0.8% | -3.8% | -3.2% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.38 | $1.36 | -1.4% | +0.7% | +7.9% | +0.7% | +2.6% | -12.3% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.36 | -1.4% | +0.7% | +7.9% | +0.7% | +2.6% | -12.3% |
| Dec 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | -2.6% | +6.8% | +1.3% | -3.1% | +5.2% |
| Dec 2 | BTIG | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | -2.6% | +6.8% | +1.3% | -3.1% | +5.2% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.10 | $2.09 | -0.5% | +0.0% | +5.2% | -4.1% | -1.4% | +1.4% |
| Oct 29 | BTIG | Maintains | Buy → Buy | — | $3.09 | $2.16 | -30.1% | -32.0% | +0.0% | +5.2% | -4.1% | -1.4% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.88 | $1.83 | -2.7% | -5.9% | +0.0% | -5.1% | +1.2% | -8.8% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.69 | $1.77 | +4.7% | +33.7% | +6.2% | +6.2% | +11.4% | -28.2% |
| Mar 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.69 | $1.77 | +4.7% | +33.7% | +6.2% | +6.2% | +11.4% | -28.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.38 | -0.4% | +0.0% | -0.4% | -3.4% | -0.4% | +0.4% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.90 | +1.6% | +1.1% | +2.6% | -0.5% | +7.3% | +14.5% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.64 | $1.69 | +3.0% | -3.0% | -0.6% | +0.6% | +2.5% | +4.9% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.28 | $1.28 | +0.0% | +0.0% | +3.1% | +0.0% | -0.8% | +1.5% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.30 | -1.5% | +0.0% | -3.0% | +0.0% | +3.1% | +0.0% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.39 | +0.7% | -2.2% | +5.2% | +4.2% | -2.7% | +0.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.11 | $1.17 | +5.4% | +10.8% | +8.9% | +0.7% | +6.7% | +0.0% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.24 | $2.47 | +10.3% | -18.3% | -10.9% | -3.1% | -5.7% | +1.3% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.37 | $1.60 | +16.8% | +24.1% | +11.2% | -3.2% | +6.0% | +5.2% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.99 | $1.02 | +3.1% | +1.1% | +2.0% | -3.4% | +0.5% | +1.0% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.17 | $1.21 | +3.4% | -1.7% | -2.6% | +1.8% | +0.9% | -8.7% |
| Aug 28 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $1.15 | $1.23 | +7.0% | +20.0% | +11.6% | -9.1% | -0.7% | -4.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.47 | $1.38 | -6.1% | -14.3% | +4.8% | -0.8% | -3.8% | -0.8% |
| Jun 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.13 | $1.13 | +0.0% | -3.5% | -3.7% | -2.9% | -10.8% | +2.2% |
| Jun 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.23 | $1.24 | +0.8% | -4.1% | -3.4% | -2.6% | +1.8% | -3.5% |
| Jun 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.09 | $1.12 | +2.8% | +0.9% | +1.8% | +7.1% | +6.7% | -2.3% |
| May 31 | Piper Sandler | Upgrade | Neutral → Overweight | — | $0.96 | $1.12 | +16.8% | +8.4% | +4.8% | +0.9% | +1.8% | +7.1% |
| May 30 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.13 | $1.26 | +11.5% | -15.1% | +8.4% | +4.8% | +0.9% | +1.8% |
| May 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.21 | $1.21 | +0.0% | -6.6% | -15.1% | +8.4% | +4.8% | +0.9% |
| Apr 26 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.71 | $0.71 | -0.3% | +11.1% | +15.0% | -0.3% | -4.0% | +1.3% |
| Feb 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.65 | $0.67 | +3.1% | +5.8% | +6.9% | +11.5% | -1.1% | +3.3% |
| May 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $0.45 | $0.35 | -20.9% | -15.4% | -2.9% | -9.5% | +3.6% | -4.6% |
| Mar 31 | Piper Sandler | Downgrade | Overweight → Neutral | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Mar 31 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Mar 31 | Mizuho | Downgrade | Buy → Neutral | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Mar 31 | Needham | Downgrade | Buy → Hold | — | $0.83 | $0.78 | -5.9% | -13.4% | -7.0% | -1.3% | -8.2% | -5.8% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.77 | $2.88 | +4.0% | +6.5% | -2.7% | +0.0% | -1.0% | -1.4% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.41 | $3.52 | +3.2% | -2.3% | +8.1% | -2.2% | +5.7% | -3.0% |
| Jan 29 | JP Morgan | Downgrade | Neutral → Underweight | — | $3.43 | $3.36 | -2.0% | -5.5% | +5.2% | +2.6% | +12.6% | -1.8% |
| Oct 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.18 | $3.10 | -2.5% | -10.7% | -14.8% | -3.3% | -3.0% | -2.2% |
| Sep 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.65 | $2.83 | +6.8% | +2.6% | -4.4% | +1.9% | -1.9% | -2.7% |
| Sep 4 | BTIG | Maintains | Buy → Buy | — | $2.65 | $2.83 | +6.8% | +2.6% | -4.4% | +1.9% | -1.9% | -2.7% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.65 | $2.83 | +6.8% | +2.6% | -4.4% | +1.9% | -1.9% | -2.7% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.91 | $12.26 | +2.9% | +3.7% | -0.6% | +0.7% | +4.2% | -3.4% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | Mizuho | Maintains | Buy → Buy | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
| May 6 | JP Morgan | Maintains | Overweight → Overweight | — | $11.95 | $11.95 | +0.0% | -2.6% | +0.3% | +2.6% | +7.3% | -10.0% |
No insider trades available.
8-K · 2.02
!! High
Akebia Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Akebia Therapeutics reported quarterly earnings results via press release, with the full financial details available in the furnished exhibit for investor review.
May 7
8-K
Unknown — 8-K Filing
A new director's option grant at $1.41 suggests management expects stock appreciation, but the low strike price indicates current valuation challenges that investors should monitor carefully.
Apr 1
8-K
Unknown — 8-K Filing
Q32 Bio's upcoming 36-week topline results for bempikibart in alopecia areata represent a critical near-term catalyst that could validate the drug candidate and significantly impact the stock's valuation.
Mar 10
8-K
Seres Therapeutics, Inc. -- 8-K Filing
Seres Therapeutics appointed a new executive with proven experience leading anemia programs at Akebia and managing acquisitions, strengthening its operational and clinical development capabilities.
Mar 2
8-K
Akebia Therapeutics, Inc. -- 8-K Filing
Akebia Therapeutics reports full-year 2025 results with positive early 2026 commercial momentum for its kidney disease treatment Vafseo, suggesting improved market adoption following its first-year launch.
Feb 26
Data updated apr 24, 2026 5:05pm
· Source: massive.com